



KOLINPHARMA®  
LEADER TO HEALTH

## KOLINPHARMA®: THE SHAREHOLDERS' MEETING APPROVES THE 2017 FINANCIAL STATEMENTS

Milan, May 8<sup>th</sup> 2018

The Shareholders' Meeting of KOLINPHARMA®, Innovative SME operating in the nutraceutical sector, is called , in second calling, under Rita Paola Petrelli's chairwomanship.

### ANNUAL FINANCIAL STATEMENTS AS OF DECEMBER 31<sup>ST</sup>, 2017

The Shareholders' Meeting has reviewed and approved the financial statements as of December 31<sup>st</sup>, 2017. Sales are € 4.1M, +62.0% compared to 2016 (€ 2.5M), thanks to the strengthening of sales representatives' network and to all products' performance. The Value of Production is about € 5.3M, +41.6%, compared to 2016 (€ 3.8M).

EBITDA is about € 0.6M, +130.1% compared to 2016 (€ 0.26M). EBIT is about □ 0.03M, improved from 2016 (negative for □ 0.32M). EBT is negative for □ 0,04M (negative for □ 0.39M in 2016). The net result is negative for □ 0.07M, improved compared 2016 (negative for € 0.37M).

The Net Financial Position (NFP) is about □ 2.5M (€ 1.7M as of December 31<sup>st</sup>, 2016). The equity is about € 1.2M (€ 0.1M as of December 31<sup>st</sup>, 2016). The Capex amount to □ 1.2M for new products' development, registration of trademarks and patents and advance commissions to MSRs.

### NET RESULT DESTINATION

Shareholders' Meeting resolved to cover the loss for the financial year, about € 66,235, through the use of eventual capital increase's provisions.

The memorandum of the Shareholders' Meeting will be available for public on corporate official website [www.kolinpharma.com](http://www.kolinpharma.com) within the time and in the manner envisaged by the existing legislation.

This press release is available online on our corporate website [www.kolinpharma.com](http://www.kolinpharma.com), in the section Investor Relations > Financial Press Releases.

\*\*\*

KOLINPHARMA® S.p.A., founded in 2013, is an Innovative SME operating in nutraceutical sector and specialised in the research and development, realised internally and in collaboration with the major Italian universities. The Company's products are made of innovative and natural raw materials and have the purpose of supporting the pharmacological treatments mainly for the diseases in the orthopaedic-physiatric and gynaecological fields. KOLINPHARMA distributes the products with its brand in the whole Italian territory through a skilled sales network of 63 medical-scientific representatives (MSRs), specialised sole agents graduated in scientific disciplines. The MSRs promote KOLINPHARMA's nutraceutical products directly to doctors, pointing at the specialists' awareness. The Company's direct clients are wholesalers, that distribute to pharmacies and para-pharmacies throughout Italy. KOLINPHARMA owns 4 patents in Italy and 9 certifications, of which 2 on the company and 7 on its products.

### Contacts

IR TOP Consulting S.r.l  
Capital Markets & Investor Relations  
Floriana Vitale, Domenico Gentile  
[f.vitale@irtop.com](mailto:f.vitale@irtop.com) , [d.gentile@irtop.com](mailto:d.gentile@irtop.com)  
Via C. Cantù, 1 - 20123 Milan  
Tel.: +39 02 4547 3883/4

EnVent Capital Markets Ltd.  
Nominated Adviser (NOMAD)  
Francesca Martino  
[fmartino@enventcapitalmarkets.co.uk](mailto:fmartino@enventcapitalmarkets.co.uk)  
42 Berkeley Square - London W1J 5AW Italian  
Branch, via Barberini n. 95 - 00187 Rome  
Tel.: +39 06 896841 Fax: +39 06 89684155